<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02546622</url>
  </required_header>
  <id_info>
    <org_study_id>ATHN 2</org_study_id>
    <nct_id>NCT02546622</nct_id>
  </id_info>
  <brief_title>ATHN 2: Factor Switching Study</brief_title>
  <official_title>A Longitudinal, Observational Study of Previously Treated Hemophilia Patients Switching Factor Replacement Products</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>American Thrombosis and Hemostasis Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>CSL Behring</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bioverativ Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>American Thrombosis and Hemostasis Network</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a longitudinal, observational study of patients with Hemophilia A or B who are
      planning to switch to a newly approved coagulation factor replacement product, or who have
      recently switched factor products. The study will follow each patient for up to 1 year.
      Patients will be recruited at Hemophilia Treatment Centers (HTC) which are ATHN-affiliates.
      The primary outcome being studied is the development of inhibitor (i.e., antibodies to
      factor) at 1 year or 50 exposure days, whichever comes first.

      The study will be conducted at approximately 30 HTCs, with a planned enrollment of 600
      patients.The entire study duration is projected to be approximately 6 years.

      In addition, optional substudies will be included for some products, as &quot;Product-Specific
      Modules&quot;. These will be questionnaires to collect data for subjects receiving selected Factor
      products. For example, subjects receiving Eloctate will be approached to participate in the
      'Eloctate Product-Specific Module'; subjects receiving Adynovate will be approached to
      participate in the 'Adynovate Product-Specific Module'. Questions will be related to product
      use, perceptions of product use, and other post-marketing consumer data.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This non-interventional, minimal risk cohort study will enroll patients with Hemophilia A or
      B who are planning or have recently switched to a new Factor product. The study will have 2
      Arms, prospective and retrospective. The Prospective Arm will enroll patients who plan to
      switch to a new factor. The Retrospective Arm will enroll patients who have recently switched
      to a new factor (within the previous 50 weeks). Patient will be seen at baseline and for up
      to 4 additional visits, and quarterly follow-up by phone. Required study visits will be
      planned to coincide with routine follow-up visits whenever possible.

      Please note that Factor Replacement Products are not being provided by the study.

      The primary objective is to assess and characterize the rate of inhibitor development within
      one (1) year or fifty (50) exposure days, whichever is first, after switching clotting factor
      replacement products in previously treated patients (PTPs) with hemophilia A or B.

      Data collected will include eligibility, demographics, medical history, hemophilia history
      (clotting history, product history, genotype and family history), inhibitor history,
      co-morbidities at baseline (i.e., HIV, Hepatitis C.), detailed clotting factor replacement
      product(s) usage and switching plan, and reasons for switching factor products. Also targeted
      physical exams will be performed at baseline and during follow-up, and targeted concomitant
      medication data will be collected. Data collection will also include patient-reported
      outcome(s) after 1 year, bleeding events, surgeries, laboratory Inhibitor testing and details
      regarding testing methodology, pharmacokinetic (PK) data (if known), new diagnoses, and
      co-morbidities (targeted), Safety/Adverse Events using European Union Hemophilia Safety
      Surveillance (EUHASS) definitions.

      This study will evolve to include any newly approved (since January 2013) factors as they
      come to market. Cohorts will be defined by the brand/type of new clotting factor replacement
      product approved after January 1, 2013. The current list of specific new Factor VIII
      replacement products include Eloctate® (Bioverativ) and NovoEight® (NovoNordisk); Factor IX
      replacement products include Alprolix® (Bioverativ), Rixubis® (Baxalta) and IXinity®
      (Emergent Biosolutions). Others are imminent.

      The over-arching rationale for this protocol is that a pragmatic study which is consistent
      with real world practices across a wide range of patients that is not principally tied to a
      particular manufacturer or product may be of great advantage to the entire hemophilia
      community.

      Study Duration

        -  Subjects on prophylaxis will be followed on study for up to 1 year. Each subject will be
           seen during a study visit or contacted by telephone at least once every 3 months (i.e.,
           quarterly). Patients may participate for multiple 'cycles', if they switch factor
           products more than once while the study is actively recruiting.

      Treatment regimen will be at the discretion of the subject's hemophilia caregivers. No
      treatment is being provided by the study.

        -  Substudies A number of substudies are planned with pharmaceutical sponsors to collect
           information from patients about their products' use. Participation in these optional
           substudies (product-specific modules) will be planned to coincide with study visits.
           These modules will collect information from subjects about their perception and use of
           factor use/treatment, physical activity levels and other general health questions. These
           data will be collected via questionnaire, primarily via phone.

      Concomitant and Excluded Therapies

        -  Immune tolerance therapy is excluded on study. This includes immunosuppressive
           treatments used to eradicate inhibitors. Steroid treatments for allergic disorders and
           asthma, are allowed.

      Data Collection System

        -  All data collected will be entered into electronic case report forms (eCRFs) within the
           secure ATHN Study Manager system. Subject Identifiers (IDs) will be generated in
           Clinical Manager.

        -  Reimbursement will be managed by each participating HTC. Most study centers will
           reimburse study subjects for travel and parking, but this varies by center.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Inhibitor Development</measure>
    <time_frame>After 50 Exposure Days or 1 Year, whichever comes first</time_frame>
    <description>Inhibitor development is the primary outcome. Subjects will be followed closely and tested at baseline, after 10 Exposure Days and 50 Exposure Days, and/or at 1 year. Specimens will be submitted to local laboratories and evaluated for inhibitor titers, and inhibitors will be confirmed by local laboratories and CDC.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inhibitor Development</measure>
    <time_frame>10 days</time_frame>
    <description>To determine the prospective incidence of inhibitor development after 10 exposure days to a new, novel recombinant factor following a switch from another clotting factor replacement product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of risk factors for inhibitor development</measure>
    <time_frame>1 year</time_frame>
    <description>To compare the prevalence of selected risk factors in patients with hemophilia who develop inhibitors following switching to a new product, to those found in subjects who do not develop inhibitors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Targeted post-marketing approval safety and efficacy data</measure>
    <time_frame>1 year</time_frame>
    <description>To collect and summarize targeted post-marketing approval safety and efficacy data for events related to clotting factor replacement products, specifically
To collect data on bleeding events following switching factor.
To summarize replacement factor product dosing regimens prescribed to the study population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platform for additional substudies</measure>
    <time_frame>1 year</time_frame>
    <description>To serve as a platform for product-specific questionnaires in cohorts of patients who switch to a particular product.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Hemophilia</condition>
  <arm_group>
    <arm_group_label>Arm A Prospective</arm_group_label>
    <description>Patients who are switching to a new Factor VIII and Factor IX Replacement Product for Hemophilia A and B which was FDA approved after January 1, 2013.
These patients will be followed prospectively for up to 1 year.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B Retrospective</arm_group_label>
    <description>Patients who have recently switched to a new Factor VIII and Factor IX Replacement Product for Hemophilia A and B which was FDA approved after January 1, 2013.
Patients must have switched products within the past 50 weeks at the time of enrollment.
These patients will be assessed retrospectively and/or followed prospectively for up to 1 year.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Factor VIII Replacement Products for Hemophilia which were FDA approved after January 1, 2013</intervention_name>
    <description>Prophylaxis for prevention of bleeding, various regimens.</description>
    <arm_group_label>Arm A Prospective</arm_group_label>
    <arm_group_label>Arm B Retrospective</arm_group_label>
    <other_name>Eloctate®</other_name>
    <other_name>NovoEight®</other_name>
    <other_name>Adynovate®</other_name>
    <other_name>Nuwiq®</other_name>
    <other_name>Afstyla®</other_name>
    <other_name>Kovaltry®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Factor IX Replacement Products for Hemophilia which were FDA approved after January 1, 2013</intervention_name>
    <description>Prophylaxis for prevention of bleeding, various regimens.</description>
    <arm_group_label>Arm A Prospective</arm_group_label>
    <arm_group_label>Arm B Retrospective</arm_group_label>
    <other_name>Alprolix®</other_name>
    <other_name>Rixubis®</other_name>
    <other_name>IXinity®</other_name>
    <other_name>Idelvion®</other_name>
    <other_name>Rebinyn®</other_name>
  </intervention>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma drawn at baseline, after 10 Exposure Days, after 50 Exposure Days, and at study end (1
      year). If inhibitor suspected, sample will be drawn and tested locally, and within 2 weeks of
      first positive inhibitor, a confirmatory sample will be drawn and sent to CDC. Patients may
      be co-enrolled in other ATHN studies such as My Life Our Future, will performs genotype
      Samples may be linked in patient who have authorized
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study will enroll approximately 600 patients with hemophilia who meet the eligibility
        criteria and are receiving care from one of the ATHN-affiliated Hemophilia Treatment
        Centers (HTC). There will be 2 arms:

        Arm A (Prospective) will include patients who are switching factor replacement products and
        will be followed prospectively for up to 1 year.

        Arm B (Retrospective) will include patients who have switched factor replacement products
        previously (within the past 50 weeks at the time of enrollment). These patients will be
        assessed retrospectively and/or followed prospectively for up to 1 year.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Moderate or Severe Congenital Hemophilia A or B (FVIII or FIX clotting activity less
             than or equal to 5% of normal).

          -  Able to give informed consent (by patient or parent/authorized guardian).

          -  Previously treated with plasma-derived or recombinant clotting factor replacement
             products with at least 50 exposure days (as assessed either from direct clinical
             records in children under age 5, or by clinical history of dosing in older patients).
             For Arm B being enrolled retrospectively, this previous treatment must be prior to
             product switch under study.

          -  Planning to switch, or recently switched within the previous 50 weeks, to a new brand
             or type of replacement factor VIII or IX, FDA approved after January 1, 2013.

          -  Arm B only: Negative inhibitor screen within the last 6 months prior to switching.

        Note: History of prior transient inhibitor or inhibitor eradicated by immune tolerance
        induction (ITI) are eligible.

        Exclusion Criteria

          -  Presence of any known bleeding disorder other than hemophilia A or B (i.e., patients
             with concurrent hemophilia and a second hemostatic defect are NOT eligible). Low Von
             Willebrand Factor (VWF) without VWF diagnosis are not excluded.

          -  Presence of an active inhibitor &gt;0.6 BU for factor VIII, &gt; 0.4 BU for factor IX at the
             time of eligibility assessment. Detection of such an inhibitor at the baseline visit
             prior to dosing with the new product (Arm A), or after dosing with new factor dosing
             (Arm B), would result in early termination without other study assessments.

          -  Currently undergoing ITI.

          -  Immunosuppressive therapy (cyclophosphamide, mycophenolate, IVIG) within 90 days and
             Rituximab within 6 months; topical steroid treatments and short course steroids for
             asthma or allergy allowed.

          -  Previous participation in Phase I, II or III interventional trials of the factor
             product being switched to.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ellis J Neufeld, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Jude Children's Research Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Janna Journeycake, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Southwest Medical Center/ Children's Hospital Dallas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ellen G McCarthy, MPH</last_name>
    <phone>800 360 2846</phone>
    <phone_ext>115</phone_ext>
    <email>emccarthy@athn.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Crystal Watson, MS</last_name>
    <phone>800 360 2846</phone>
    <phone_ext>102</phone_ext>
    <email>cwatson@athn.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California San Diego (UCSD)</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilana Levin</last_name>
      <phone>858-657-6384</phone>
      <email>ilevin@ucsd.edu</email>
    </contact>
    <contact_backup>
      <last_name>Rose Previte</last_name>
      <phone>858 657 6384</phone>
      <email>rprevite@ucsd.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Annette Von Drygalski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver Hemophilia and Thrombosis Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Kula</last_name>
      <phone>303-724-0363</phone>
      <email>Kristi.Norton@ucdenver.edu</email>
    </contact>
    <contact_backup>
      <last_name>Molly Brown</last_name>
      <phone>303 724-0363</phone>
      <email>molly.a.brown@ucdenver.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale Hemophilia Treatment Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evangelina Louizos</last_name>
      <phone>203-785-4011</phone>
      <email>e.louizos@yale.edu</email>
    </contact>
    <contact_backup>
      <last_name>Susan Marino</last_name>
      <phone>(203) 785-4011</phone>
      <email>susan.marino@yale.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Salley Pels, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gary Kupfer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chris Guelcher, RN</last_name>
      <phone>202-476-3622</phone>
      <email>cguelche@childrensnational.org</email>
    </contact>
    <contact_backup>
      <last_name>Cami Hawkins</last_name>
      <phone>202 476 3578</phone>
      <email>mailto:camhawki@childrensnational.org</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Guerrera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins All Children's Hospital</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mike Gates</last_name>
      <phone>727-767-4178</phone>
      <email>mgates7@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mary Ann Cardenas, RN</last_name>
      <phone>727) 767-4931</phone>
      <email>mcarden4@jhmi.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Irmel Ayala, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Children's Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Manns, RN</last_name>
      <phone>813-870-0848</phone>
      <email>jennifer.manns@baycare.org</email>
    </contact>
    <contact_backup>
      <last_name>Sara Nixon, RN</last_name>
      <phone>813 554 8294</phone>
      <email>sara.nixon@baycare.org</email>
    </contact_backup>
    <investigator>
      <last_name>Erin Cockrell, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark Mogul, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta/Emory</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lasandra Patterson, RN</last_name>
      <phone>404-727-9698</phone>
      <email>lasandra.patterson@emory.edu</email>
    </contact>
    <contact_backup>
      <last_name>Gladys Lee</last_name>
      <phone>404 727 9698</phone>
      <email>gladys.lee@emory.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Robert Sidonio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shannon Meeks, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Glaivy Batsuli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carolyn Bennett, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bleeding and Clotting Disorders Institute</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Gonzales</last_name>
      <phone>309-692-5337</phone>
      <phone_ext>135</phone_ext>
      <email>sarah@ilbcdi.org</email>
    </contact>
    <contact_backup>
      <last_name>Tianna Horgan</last_name>
      <phone>309 692 5337</phone>
      <phone_ext>136</phone_ext>
      <email>tianna@ilbcdi.org</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Tarantino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jonathon Roberts, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana Hemophilia and Thrombosis Center (IHTC)</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tasia Weiss</last_name>
      <phone>317-871-0011</phone>
      <phone_ext>289</phone_ext>
      <email>nweiss@ihtc.org</email>
    </contact>
    <contact_backup>
      <last_name>Kat Molitor</last_name>
      <phone>317 871 0011</phone>
      <phone_ext>287</phone_ext>
      <email>kmolitor@ihtc.og</email>
    </contact_backup>
    <investigator>
      <last_name>Amy Shapiro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Louisiana Center for Bleeding and Clotting Disorders</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melody Benton</last_name>
      <phone>504-988-3596</phone>
      <email>mbenton@tulane.edu</email>
    </contact>
    <investigator>
      <last_name>Tamuella Singleton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maine Hemophilia and Thrombosis Center</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Moore</last_name>
      <phone>207-396-7312</phone>
      <email>amoore@mmc.org</email>
    </contact>
    <contact_backup>
      <last_name>Glen Roy, RN</last_name>
      <phone>207 396 7683</phone>
      <email>royg@mmc.org@mmc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Eric Larsen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tracey Weatherbie, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trish Underland, RN</last_name>
      <phone>410-614-0834</phone>
      <email>punderl1@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Olivia Gordon, RN</last_name>
      <phone>410 955 6214</phone>
      <email>ogordon2@jhmi.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Cliff Takemoto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Streiff, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston Hemophilia Center at Children's Hospital of Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tien Hua</last_name>
      <phone>617-919-6407</phone>
      <email>Tien.Hua@childrens.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Stacy Croteau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pavan Gonchi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Loren D'Angelo, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Hemophilia and Coagulation Disorders Program</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Hauker</last_name>
      <phone>734-936-5905</phone>
      <email>rhauke@umich.med.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jim Munn, RN</last_name>
      <phone>734 936-6393</phone>
      <email>jmunn@umich.med.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Steven Pipe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jim Munn, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Michigan State University Center for Bleeding and Clotting Disorders</name>
      <address>
        <city>East Lansing</city>
        <state>Michigan</state>
        <zip>48823</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Anderson, LPN</last_name>
      <phone>517-353-9385</phone>
      <email>kathleen.anderson@hc.msu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Julie Rose, RN</last_name>
      <phone>517 353 9385</phone>
      <email>julie.rose@@hc.msu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Roshni Kulkarni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Renuka Gera, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Diane MacDonald, MD, FACP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ajovi Scott-Emuakpor, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aghad Chamdin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Santosh Hammond, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laura Carlson, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debbie Nelson</last_name>
      <phone>816-302-6854</phone>
      <email>dnelson@cmh.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sarah Streeter, RN</last_name>
      <phone>816 302 6845</phone>
      <email>sstreeter@cmh.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Brian Wicklund, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shannon Carpenter, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Silvey, DO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eryn Bilynsky, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew Wilson, RN, FNP-C</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Melissa Armanees, RN, CPNP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rebecca Coney, DNP, FNP-C</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Comprehensive Hemophilia and Thrombosis Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurel McKernan, RN</last_name>
      <phone>603-650-5486</phone>
      <email>Laurel.J.Mckernan@Hitchcock.org</email>
    </contact>
    <investigator>
      <last_name>Debra Ornstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilene Goldberg</last_name>
      <phone>212-746-3403</phone>
      <email>igoldber@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Catherine McGuinn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mary M. Gooley Hemophilia Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14621</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Bennett</last_name>
      <phone>585-922-5006</phone>
      <email>Deborah.Bennett@rochesterregional.org</email>
    </contact>
    <contact_backup>
      <last_name>Renee DeRider, RN</last_name>
      <phone>585-922-5700</phone>
      <email>Renee.DeRider@rochesterregional.org</email>
    </contact_backup>
    <investigator>
      <last_name>Peter Kouides, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Lattimore, RN</last_name>
      <phone>503-418-4495</phone>
      <email>lattimor@ohsu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kathy Beach</last_name>
      <phone>503 494 7425</phone>
      <email>beachk@ohsu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Recht, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia (CHOP)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stan Oliveira</last_name>
      <phone>215-590-0431</phone>
      <email>OLIVEIRAS@email.chop.edu</email>
    </contact>
    <contact_backup>
      <last_name>Menaka Dhingram</last_name>
      <phone>215 590 0431</phone>
      <email>hingramd@email.chop.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Leslie Raffini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pennsylvania Comprehensive Hemophilia and Thrombophilia Program / Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Panercki</last_name>
      <phone>215-614-0506</phone>
      <email>Karen.Panckeri@uphs.upenn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mary Kelty, RN</last_name>
      <phone>215-614-0506</phone>
      <email>Mary.Kelty@uphs.upenn.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Adam Cuker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elaine Chiang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Susan Yeck, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dyanne Morris, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Hemophilia Center of Western Pennsylvania</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judith Kadosh, RN</last_name>
      <phone>412-209-7288</phone>
      <email>jkadosh@itxm.org</email>
    </contact>
    <contact_backup>
      <last_name>Jacqueline Washington, BS</last_name>
      <phone>412 209 7263</phone>
      <email>jwashington@itxm.org</email>
    </contact_backup>
    <investigator>
      <last_name>Margaret Ragni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lynn Malec Malec, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Craig Seaman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kevin Stiegler, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivia McGregor</last_name>
      <phone>901-595-6411</phone>
      <email>olivia.mcgregor@stjude.org</email>
    </contact>
    <investigator>
      <last_name>Ulrike Reiss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ellis Neufeld, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Akram Meslah Shayeb, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Melissa Lee, PA-C</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UTSW Medical Center at Dallas/Children's Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Winborn</last_name>
      <phone>214-456-2888</phone>
      <email>anna.winborn@childrens.org</email>
    </contact>
    <contact_backup>
      <last_name>Leah Adix</last_name>
      <phone>214 456 2888</phone>
      <email>leah.adix@childrens.org</email>
    </contact_backup>
    <investigator>
      <last_name>Janna Journeycake, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Niavana Solos, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michele Carlin, PNP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ayesha Zia, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of the Kings Daughters, Inc.</name>
      <address>
        <city>Suffolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reshil-Marie Dukes</last_name>
      <phone>757-688-8291</phone>
      <email>reshil-marie.dukes@chkd.org</email>
    </contact>
    <investigator>
      <last_name>Gary Woods, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington Center for Bleeding Disorders Bloodworks Northwest d/b/a Puget Sound Blood Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Schmitter</last_name>
      <phone>206-689-6539</phone>
      <email>sophies@bloodworksnw.org</email>
    </contact>
    <investigator>
      <last_name>Rebecca Kruse-Jarres, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Barbara Konkle, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Blood Center of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Stephany</last_name>
      <phone>414-257-2424</phone>
      <email>karen.stephany@bcw.edu</email>
    </contact>
    <contact_backup>
      <last_name>Megan Lemancyzk</last_name>
      <phone>414 257 2424</phone>
      <email>megan.lemancyzk@bcw.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Joan Gill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shawn Jobe, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ken Friedman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www2a.cdc.gov/ncbddd/htcweb/Dir_Report/Dir_Search.asp</url>
    <description>Hemophilia Treatment Center Directory</description>
  </link>
  <reference>
    <citation>Josephson CD, Abshire T. The new albumin-free recombinant factor VIII concentrates for treatment of hemophilia: do they represent an actual incremental improvement? Clin Adv Hematol Oncol. 2004 Jul;2(7):441-6.</citation>
    <PMID>16163220</PMID>
  </reference>
  <reference>
    <citation>Powell JS. Lasting power of new clotting proteins. Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):355-63. doi: 10.1182/asheducation-2014.1.355. Epub 2014 Nov 18. Review.</citation>
    <PMID>25696879</PMID>
  </reference>
  <reference>
    <citation>Ragni, MV, Kessler, CM, and Lozier, JN (2009). Clinical aspects and therapy for hemophilia, in Hoffman R, Benz EJ, Shattil, SJ et al eds, Hematology, Basic Principles and Practice, 5th Edition, Churchill Livingstone, Philadelphia, pp 1911-1930.</citation>
  </reference>
  <reference>
    <citation>Abshire TC, Brackmann HH, Scharrer I, Hoots K, Gazengel C, Powell JS, Gorina E, Kellermann E, Vosburgh E. Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy--International Kogenate-FS Study Group. Thromb Haemost. 2000 Jun;83(6):811-6.</citation>
    <PMID>10896230</PMID>
  </reference>
  <reference>
    <citation>Mahlangu J, Powell JS, Ragni MV, Chowdary P, Josephson NC, Pabinger I, Hanabusa H, Gupta N, Kulkarni R, Fogarty P, Perry D, Shapiro A, Pasi KJ, Apte S, Nestorov I, Jiang H, Li S, Neelakantan S, Cristiano LM, Goyal J, Sommer JM, Dumont JA, Dodd N, Nugent K, Vigliani G, Luk A, Brennan A, Pierce GF; A-LONG Investigators. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood. 2014 Jan 16;123(3):317-25. doi: 10.1182/blood-2013-10-529974. Epub 2013 Nov 13.</citation>
    <PMID>24227821</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2015</study_first_submitted>
  <study_first_submitted_qc>September 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2015</study_first_posted>
  <last_update_submitted>January 9, 2018</last_update_submitted>
  <last_update_submitted_qc>January 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Factor</keyword>
  <keyword>Coagulation</keyword>
  <keyword>Inhibitor</keyword>
  <keyword>HTC</keyword>
  <keyword>Bleeding</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Product-Specific Module data for subjects enrolled in each module will be shared with each sponsor, as appropriate.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

